Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to "Methodological Considerations Regarding Facility Volume and Travel Distance in Laryngeal Squamous Cell Carcinoma".

Head & neck·2026
Same author

Family experiences of receiving treatment recommendations in a precision medicine trial for poor-prognosis childhood cancer.

NPJ genomic medicine·2026
Same author

Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.

Future oncology (London, England)·2026
Same author

Association of Facility Case Volume and Patient Travel Distance With Survival in Laryngeal Squamous Cell Carcinoma.

Head & neck·2026
Same author

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.

Nature communications·2026
Same author

BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.

International journal of clinical oncology·2026

Related Experiment Video

Updated: Jan 16, 2026

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

9.1K

High-throughput 3D engineered paediatric tumour models for precision medicine.

MoonSun Jung1,2, Valentina Poltavets1,3,4, Joanna N Skhinas1,4

  • 1Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, 2052, Australia.

Molecular Systems Biology
|October 1, 2025
PubMed
Summary

Researchers developed patient-specific tumouroids using 3D bioprinting and engineered hydrogels. This precision medicine approach enables rapid drug sensitivity testing for paediatric cancers, overcoming traditional sample limitations.

Keywords:
3D BioprintingHigh-throughput (HTP) Drug ScreeningPaediatric CancerPreclinical ModelsTumouroid Models

More Related Videos

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

9.5K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.6K

Related Experiment Videos

Last Updated: Jan 16, 2026

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

9.1K
Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

9.5K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.6K

Area of Science:

  • Oncology
  • Biotechnology
  • Materials Science

Background:

  • Precision medicine requires effective drug sensitivity profiling for personalized cancer therapy.
  • Current methods for generating patient-derived tumour models for high-throughput (HTP) screening are time-consuming and often unsuccessful.
  • Obtaining adequate biopsy samples for HTP screening presents a significant challenge in paediatric oncology.

Purpose of the Study:

  • To develop a novel platform for creating patient-specific paediatric tumour models.
  • To overcome limitations in sample acquisition and model generation for precision medicine in paediatric cancers.
  • To enable rapid and accurate drug sensitivity profiling for individualised cancer treatment.

Main Methods:

  • Utilized gene expression analysis of paediatric neuroblastoma and sarcoma cohorts to identify key extracellular matrix (ECM) components.
  • Engineered hydrogel systems incorporating ECM-mimic peptides for 3D bioprinting.
  • Created patient-specific tumouroids using patient-derived cells from xenograft models and direct patient tumour samples.

Main Results:

  • Bioprinted tumouroids successfully recapitulated the genetic and phenotypic characteristics of original tumours, including tumourigenicity.
  • The engineered ECM hydrogel system facilitated the creation of patient-specific tumouroids.
  • High-throughput drug screening on these tumouroids identified individualised drug sensitivities.

Conclusions:

  • Developed a timely and clinically relevant technology platform for precision medicine in paediatric cancers.
  • The 3D bioprinting approach using engineered ECM hydrogels offers a viable alternative to traditional tumour model generation.
  • This platform has the potential to transform preclinical testing and advance personalised treatment strategies for various paediatric cancers.